View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Oct. 31, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	0001095981
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding		13,201,410
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 6,806	$ 9,550
Accounts receivable, net of reserves of $185 in 2018 and $167 in 2017	440	145
Restricted cash	40	675
Inventories, net	2,814	3,183
Other current assets	654	1,311
Total current assets	10,754	14,864
Property and equipment, net	2,648	3,052
Other assets	1,938	2,570
Intangibles, net	6,270	7,207
Goodwill	3,922	3,922
Total assets	25,532	31,615
Current liabilities:
Accounts payable and accrued expenses	3,645	4,790
Term loan obligations, net of discount	14,007	13,624
Total current liabilities	17,652	18,414
Deferred revenues	187	94
Long-term deferred rent and other	83	107
Warrant liability	1,472
Total liabilities	19,394	18,615
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 23,500 shares issued; 4,624 and 2,431 shares outstanding in 2018 and 2017, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 11,691,293 and 5,782,573 shares issued and outstanding in 2018 and 2017, respectively	67	58
Additional paid-in capital	417,036	413,304
Accumulated other comprehensive income	1,182	1,387
Accumulated deficit	(412,147)	(401,749)
Total stockholders’ equity	6,138	13,000
Total liabilities and stockholders’ equity	$ 25,532	$ 31,615

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Accounts receivable, reserves	$ 185	$ 167
Stockholders’ equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	23,500	23,500
Preferred stock, shares outstanding (in shares)	4,624	2,431
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	11,691,293	5,782,573
Common stock, shares outstanding (in shares)	11,691,293	5,782,573

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Product revenues	$ 858	$ 467	$ 2,249	$ 2,027
Cost of product revenues	322	181	918	992
Amortization of intangible assets	306	306	919	919
Gross profit (loss)	230	(20)	412	116
Development revenues:
Government contracts and other	454	1,306	2,270	2,856
Total development revenues	454	1,306	2,270	2,856
Operating expenses:
Research and development	1,916	3,004	6,366	9,284
Sales and marketing	453	840	1,656	3,043
General and administrative	1,486	1,785	5,199	6,012
Change in fair value of warrants	(1,676)		(1,676)	0
Total operating expenses	2,179	5,629	11,545	20,025
Operating loss	(1,495)	(4,343)	(8,863)	(17,053)
Other income (expense):
Interest income	11	5	30	24
Interest expense	(512)	(474)	(1,379)	(1,603)
Other income (expense), net	9	5	157	233
Issuance costs of warrants	(343)		(343)	0
Total other expense	(835)	(464)	(1,535)	(1,346)
Net loss	(2,330)	(4,807)	(10,398)	(18,399)
Beneficial conversion feature for convertible preferred stock	(2,487)		(2,487)
Net loss allocable to common stockholders	$ (4,817)	$ (4,807)	$ (12,885)	$ (18,399)
Basic and diluted net loss per share attributable to common stockholders	$ (0.55)	$ (1.39)	$ (1.85)	$ (6.22)
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders	8,716,194	3,449,083	6,972,615	2,956,403
Comprehensive loss:
Net loss	$ (2,330)	$ (4,807)	$ (10,398)	$ (18,399)
Other comprehensive loss – foreign currency translation adjustments	(55)	16	(205)	(59)
Comprehensive loss	$ (2,385)	$ (4,791)	(10,603)	(18,458)
Assets Purchased from Azaya Therapeutics, Inc. [Member]
Operating expenses:
In process research and development acquired from Azaya Therapeutics			$ 0	$ 1,686

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (10,398)	$ (18,399)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,465	1,618
Amortization of deferred financing costs and debt discount	383	580
Provision for excess inventory	433	413
Allocation of issuance costs associated with warrants	343	0
Change in fair value of warrants	(1,676)	0
Share-based compensation expense	325	588
Loss on asset disposal	23	9
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	(316)	991
Inventories	615	457
Other current assets	514	(284)
Other assets	7	74
Accounts payable and accrued expenses	(1,274)	(1,746)
Deferred revenues	93	6
Long-term deferred rent	(24)	103
Net cash used in operating activities	(9,487)	(13,904)
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	(128)	(271)
Proceeds from sale of assets	0	10
Net cash used in investing activities	(128)	(1,462)
Cash flows from financing activities:
Principal payments on long-term obligations	0	(4,720)
Proceeds from sale of common and preferred stock, net	6,246	12,377
Net cash provided by financing activities	6,246	7,657
Effect of exchange rate changes on cash and cash equivalents	(10)	11
Net decrease in cash and cash equivalents	(3,379)	(7,698)
Cash, cash equivalents, and restricted cash at beginning of period	10,225	12,910
Cash, cash equivalents, and restricted cash at end of period	6,846	5,212
Cash paid during period for:
Interest	990	1,059
Supplemental schedule of non-cash investing and financing activities:
Conversion of preferred stock into common stock	7	0
Assets Purchased from Azaya Therapeutics, Inc. [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
In process research and development acquired from Azaya Therapeutics	0	1,686
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	0	(1,201)
Supplemental schedule of non-cash investing and financing activities:
Common stock issued in payment for the assets acquired	$ 0	$ 2,311

Basis of Presentation and New Accounting Standards

9 Months Ended

Sep. 30, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Presentation and New Accounting Standards

1.	Basis of Presentation and New Accounting Standards

Our accompanying unaudited consolidated condensed financial statements as of September 30, 2018 and for the three and nine months ended September 30, 2018 and 2017 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at December 31, 2017 has been derived from the audited financial statements at December 31, 2017, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (collectively, the “Company”) have been included. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 9, 2018.

Amendments to Certificate of Incorporation and Reverse Stock Split

On May 23, 2018, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Amendment”), with the Secretary of State of the State of Delaware to (i) effectuate a one-for-ten (1:10) reverse stock split (the “Reverse Stock Split”) of its common stock, par value $0.001 per share, without any change to its par value, and (ii) increase the number of authorized shares of the Company’s common stock from 75 million to 100 million shares (which amount is not otherwise affected by the Reverse Stock Split). The Amendment became effective on the filing date. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company’s common stock (x) issued and outstanding decreased from approximately 61.6 million shares (as of May 23, 2018) to approximately 6.2 million shares; (y) reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 23.4 million shares to approximately 2.3 million shares, and (z) reserved but unallocated under our current equity incentive plans (including the stockholder-approved share increase to the Company’s 2014 Equity Incentive Plan) decreased from approximately 9.1 million common shares to approximately 0.9 million common shares. The Company’s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Proportional adjustments for the reverse stock split were made to the Company's outstanding stock options, warrants and equity incentive plans for all periods presented.

Recently Issued and Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases. Under this new guidance, at the commencement date, lessees will be required to recognize (i) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and (ii) a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. This guidance is not applicable for leases with a term of 12 months or less. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted. Although ASU 2016-02 is required to be adopted at the earliest period presented using a modified retrospective approach, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which allows for an alternative transition method of adoption by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company plans to adopt ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11. Although the Company is in the process of evaluating the impact the adoption of ASU 2016-02 will have on its financial statements, the Company expects the most significant changes will be the recognition of right-of-use assets and lease liabilities on the Company’s balance sheet for its real estate operating lease commitments.

In February 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, to simplify how all entities assess goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As amended, the goodwill impairment test will consist of one step comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact that this standard will have on our consolidated financial statements.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 31, 2018, with early adoption permitted. We are currently evaluating the impact that this standard will have on our consolidated financial statements.

Recently Adopted Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services. ASU 2014-09 and all subsequent amendments (collectively, the “new standards”) may be applied using either the full retrospective method, in which case the standard would be applied to each prior reporting period presented, or the modified retrospective method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application. We have adopted the standards beginning this first quarter of 2018 using the modified retrospective method. Overall, the timing or amounts related to the revenue recognition under the new standards did not differ from our previously applied revenue recognition policy. Our product revenues are recognized at a point in time, which is when control transfers to the customer. We have made an accounting policy election to treat shipping and handling activities that occur after the customer obtains control of the goods as fulfillment costs. There was no cumulative effect of applying the new standards as of the adoption date on January 1, 2018.

In November 2016, the FASB issued ASU 2016-18, Restricted Cash, which requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The adoption of this standard, in the first quarter of 2018, changed the presentation of our statement of cash flows to include our restricted cash balance with the non-restricted cash balances. The new guidance did not have a material impact on the Company's consolidated financial statements. Cash, cash equivalents, and restricted cash reported on the consolidated condensed statements of cash flows includes restricted cash of $0.4 million, $0.4 million, $0.7 million, and $40,000 as of December 31, 2016, September 30, 2017, December 31, 2017 and September 30, 2018, respectively.

Liquidity

9 Months Ended

Sep. 30, 2018

Liquidity [Abstract]

Liquidity

We incurred net losses of $2.3 million and $10.4 million for the three and nine months ended September 30, 2018. We have an accumulated deficit of $412.1 million as of September 30, 2018. Additionally, we have used net cash of $9.5 million to fund our operating activities for the nine months ended September 30, 2018. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

Further, the Loan and Security Agreement (defined in Note 4), with Oxford Finance, LCC (“Oxford”), as further described in Note 4, requires maintaining a minimum of $1.5 million in unrestricted cash and cash equivalents on hand to avoid an event of default under the Loan and Security Agreement and requires us to make an aggregate of $7.0 million in principal payments on or before December 31, 2018. Based on our cash and cash equivalents on hand of approximately $6.8 million at September 30, 2018, the Company estimates that it will need to raise additional capital and/or obtain a waiver or restructure the Loan and Security Agreement in the near term to avoid defaulting under its $1.5 million minimum cash/cash equivalents covenant and to make an aggregate of $7.0 million in principal payments on or before December 31, 2018.

To date, these operating losses have been funded primarily from outside sources of invested capital including our recently completed 2018 Rights Offering (defined in Note 3 below), our Lincoln Park Purchase Agreement (defined in Note 11) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), the 2017 Rights Offering (defined in Note 3 below), the Loan and Security Agreement and gross profits. We have had, and we will continue to have, an ongoing need to raise additional cash from outside sources to fund our future clinical development programs and other operations. Our inability to raise additional cash would have a material and adverse impact on operations and would cause us to default on our loan.

On April 11, 2017, we entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC “Maxim”) relating to the issuance and sale of 0.9 million shares of our common stock. The price to the public in this offering was $11.00 per share. Maxim purchased the shares from us pursuant to the Underwriting Agreement at a price of $10.40 per share. The net proceeds to us from the offering were approximately $8.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed on April 17, 2017. In addition, under the terms of the Underwriting Agreement, we granted Maxim a 45-day option to purchase up to 94,400 additional shares of common stock. On May 31, 2017, Maxim exercised their overallotment option and purchased 84,900 shares at $11.00 per share. The net proceeds to us were $0.8 million, after deducting underwriting costs and offering expenses payable by us.

On September 5, 2017, we received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the last 30 consecutive business days, we no longer met the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided a period of 180 calendar days, or until March 5, 2018, in which to regain compliance. We were granted an additional compliance period of 180 calendar days, or until September 4, 2018, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital market, with the exception of the bid price requirement, and providing notice to Nasdaq of our intent to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must have been at least $1 per share for a minimum of ten consecutive business days during the second 180-day period. On June 8, 2018, we received written notice from Nasdaq that we had regained compliance with the Nasdaq Stock Market Listing Rule 5500(a)(2) concerning our minimum bid price per share of our common stock.

On November 28, 2017, we closed a rights offering originally filed under a Form S-1 registration statement in August 2017 (“2017 Rights Offering”). Pursuant to the 2017 Rights Offering, the Company sold an aggregate of 10,000 units consisting of a total of 10,000 shares of Series B Convertible Preferred Stock, immediately convertible into approximately 3,000,000 shares of common stock and 18,000,000 warrants, exercisable for an aggregate of 1,800,000 shares of common stock at an exercise price of $3.333 per share of common stock, resulting in total net proceeds to the Company of $8.8 million. These warrants became exercisable upon stockholder approval of an increase in the Company’s authorized shares of common stock obtained at the 2018 Annual Meeting of Stockholders.

On June 1, 2018, we entered into a Sales Agreement with B. Riley FBR, Inc. (“B. Riley FBR”) to sell shares of our common stock having an aggregate offering price of up to $6.5 million from time to time, through an “at the market” equity offering program (the “ATM program”) under which B. Riley FBR will act as sales agent. Through September 30, 2018, we have sold a total of 1.5 million shares for proceeds of approximately $0.8 million through the ATM program.

On July 25, 2018, we closed a rights offering originally filed under a Form S-1 registration statement in April 2018 (“2018 Rights Offering”). Pursuant to the 2018 Rights Offering, the Company sold an aggregate of 6,723 units consisting of a total of 6,723 shares of Series C Convertible Preferred Stock, immediately convertible into approximately 8.4 million shares of common stock and 7,059,150 warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.7986 per share, resulting in total net proceeds to the Company of approximately $5.7 million.

On August 28, 2018, we received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the last 30 consecutive business days, we no longer meet the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided a period of 180 calendar days, or until February 25, 2019, in which to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must have been at least $1 per share for a minimum of ten consecutive business days during the 180-day period. In the event we do not regain compliance within this 180-day period, we may be eligible to seek an additional compliance period of 180 calendar days if we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, if we provide written notice to Nasdaq of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary.

On September 21, 2018, Cytori entered into a purchase agreement and a registration rights agreement, with Lincoln Park, pursuant to which the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $5.0 million of shares of the Company’s common stock over the 24-month period following October 15, 2018, subject to the satisfaction of certain conditions. See Note 11 for further discussion on the Lincoln Park Agreement.

We continue to seek additional capital through product revenues, strategic transactions, including extension opportunities under our awarded U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (“BARDA”) contract, and from other financing alternatives. Without additional capital, current working capital and cash generated from sales will not provide adequate funding for research, sales and marketing efforts and product development activities at their current levels. If sufficient capital is not raised, we will at a minimum need to significantly reduce or curtail our research and development and other operations, and this would negatively affect our ability to achieve corporate growth goals.

Should we be unable to raise additional cash from outside sources, this would have a material adverse impact on our operations.

The accompanying consolidated condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.

Term Loan Obligations

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Term Loan Obligations

4.	Term Loan Obligations

On May 29, 2015, the Company entered into the Loan and Security Agreement, dated May 29, 2015, with Oxford (the “Loan and Security Agreement”), pursuant to which it funded an aggregate principal amount of $17.7 million (“Term Loan”), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan and Security Agreement, we were previously required to make interest only payments through June 1, 2016 and thereafter we were required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June 1, 2019, the maturity date. On February 23, 2016, we received an acknowledgement and agreement from Oxford related to the positive data on our U.S. ACT-OA clinical trial. As a result, pursuant to the Loan and Security Agreement, the period for which we are required to make interest-only payments was extended from July 1, 2016 to January 1, 2017. All unpaid principal and interest with respect to the Term Loan is due and payable in full on June 1, 2019. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, we are required to make a final payment in an aggregate amount equal to approximately $1.1 million. In connection with the Term Loan, on May 29, 2015, we issued to Oxford warrants to purchase an aggregate of 9,444 shares of our common stock at an exercise price of $103.50 per share. These warrants became exercisable as of November 30, 2015 and will expire on May 29, 2025 and, following the authoritative accounting guidance, are equity classified and its respective fair value was recorded as a discount to the debt.

On September 20, 2017, the Company entered into an amendment to the Term Loan, pursuant to which, among other things, Oxford agreed to reduce the minimum liquidity covenant level originally at $5 million to $1.5 million. The amendment also extended the interest-only period under the Loan Agreement through August 1, 2018, as the Company successfully closed on a financing and received unrestricted net cash proceeds in excess of $5 million on or before December 29, 2017.

On June 19, 2018, the Company entered into a second amendment (the “Second Amendment”) to the Term Loan with Oxford. The Second Amendment extends the interest-only period under the Term Loan to December 1, 2018 if the Company receives unrestricted gross cash proceeds of at least $15 million from the sale and issuance of the Company’s equity securities on or before August 31, 2018. The Company agreed to pay Oxford an amendment fee of $250,000 at the earlier of maturity or acceleration of the loan.

On August 31, 2018, the Company entered into a third amendment (the “Third Amendment”) to the Term Loan with Oxford. The Third Amendment extends the interest-only period under the Term Loan to December 31, 2018 and also requires that the Company pay to Oxford, in accordance with its pro rata share of the loans, 75% of all proceeds received (i) from the issuance and sale of unsecured subordinated convertible debt, (ii) in connection with a joint venture, collaboration or other partnering transaction, (iii) in connection with any licenses, (iv) from dividends (other than non-cash dividends from wholly owned subsidiaries) and (v) from the sale of any assets (such requirement, the “Prepayment Requirement”). The Prepayment Requirement does not apply to proceeds from the sale and issuance of the Company’s equity securities, other than convertible debt. The Prepayment Requirement shall apply until an aggregate principle amount of $7.0 million has been paid pursuant to the Prepayment Requirement. However, if less than $7.0 million has been paid pursuant to the Prepayment Requirement on December 31, 2018 then the Company is required to promptly make additional payments until an aggregate principal amount of $7.0 million has been paid. The Company agreed to pay Oxford an amendment fee of $50,000 at the earlier of maturity or acceleration of the loan.

The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company’s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral will be released upon the Company achieving certain liquidity level when the total principal outstanding under the Loan Agreement is less than $3 million. As of September 30, 2018, we were in compliance with all of the debt covenants under the Loan and Security Agreement.

Our interest expense for the three and nine months ended September 30, 2018 and 2017 was $0.5 million and $1.4 million and was $0.5 million and $1.6 million, respectively. Interest expense is calculated using the effective interest method, therefore it is inclusive of non-cash amortization in the amount of $0.2 million and $0.4 million for the three and nine months ended September 30, 2018 and $0.2 million and $0.6 million for the three and nine months ended September 30, 2017, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment.

The Term Loan Agreement contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by us or a declaration of material adverse change by our lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Term Loan, which could materially harm our financial condition. As of September 30, 2018, we were in compliance with all covenants under the Term Loan and have not received any notification or indication from Oxford to invoke the material adverse change clause. However, due to our current cash flow position and the substantial doubt about our ability to continue as a going concern, the entire principal amount of the Term Loan has been reclassified to short-term. We will continue to evaluate the debt classification on a quarterly basis and evaluate for reclassification in the future should our financial condition improve.

Revenue Recognition

9 Months Ended

Sep. 30, 2018

Revenue Recognition [Abstract]

Revenue Recognition

5.	Revenue Recognition

Product Sales

Our revenue is generated primarily from the sale of products. Product revenue primarily consists of sales of Celution devices and consumables for commercial and research purposes.

The Company’s contracts with customers only include one performance obligation (i.e., sale of the Company’s products). Typically, if there are multiple items included on a single order, they are delivered at the same time. Revenue is recognized at a point in time when delivery is completed and control of the promised goods is transferred to the customers. Revenue is measured as the amount of consideration the Company expects to be entitled to in exchange for those goods. The Company’s contracts do not involve financing elements as payment terms with customers are less than one year. The sale arrangements do not include any variable consideration. Advance payments from customers are recorded as deferred revenue.

Shipping and handling activities that occur after the customer obtains control of the goods are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred.

The following table represents revenue by product (in thousands):

	Three months ended				Nine months ended
	September 30, 2018		September 30, 2017		September 30, 2018		September 30, 2017
Consumable	$	692	$	389	$	1,845	$	1,338
Device		101		25		194		551
Other products		65		53		210		138
	$	858	$	467	$	2,249	$	2,027

Product revenues, classified by geographic location, are as follows (in thousands):

	Three months ended										Nine months ended
	September 30, 2018					September 30, 2017					September 30, 2018					September 30, 2017
	Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total
Americas	$	199		23	%	$	112		24	%	$	249		11	%	$	315		15	%
Japan		535		62	%		279		60	%		1,693		75	%		1,434		71	%
EMEA		114		14	%		18		4	%		262		12	%		204		10	%
Asia Pacific		10		1	%		58		12	%		45		2	%		74		4	%
Total product revenues	$	858		100	%	$	467		100	%	$	2,249		100	%	$	2,027		100	%

Concentration of Significant Customers

Two direct customers accounted for 58% of our revenue recognized for the nine months ended September 30, 2018. Three direct customers accounted for 72% of total outstanding accounts receivable (excluding receivables from BARDA) as of September 30, 2018.

Six direct customers comprised 61% of our revenue recognized for the nine months ended September 30, 2017. Four direct customers accounted for 78% of total outstanding accounts receivable as of September 30, 2017.

Development Revenue

We earn revenue for performing tasks under research and development agreements with governmental agencies like BARDA which is outside of the scope of the new revenue recognition guidance. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contracts and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $0.5 million and $2.3 million in development revenue for the three and nine months ended September 30, 2018, as compared to $1.3 million and $2.9 million for the three and nine months ended September 30, 2017.

Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Stockholders Equity Note [Abstract]

Stockholders' Equity

11.	Stockholders’ Equity

Preferred Stock

The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Company’s Board of Directors is authorized to designate the terms and conditions of any preferred stock we issue without further action by the common stockholders. There were 13,500 shares of Series A 3.6% Convertible Preferred Stock and 10,000 Series B Convertible Preferred Stock that had been issued at September 30, 2018 and December 31, 2017, respectively. There were no shares of Series A 3.6% Convertible Preferred Stock outstanding as of either date. There were 1,114 and 2,431 shares of Series B Convertible Preferred Stock outstanding as of September 30, 2018 and December 31, 2017, respectively.

On July 25, 2018, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the “Certificate of Designation”) with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.001 per share, designated as the Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The number of shares initially constituting the Series C Preferred Stock was set at 7,000 shares. Pursuant to a registration statement on Form S-1 originally filed on April 27, 2018, as amended, and became effective on July 17, 2018, and related prospectus (as supplemented), the Company registered and distributed to holders of its common stock and Series B Convertible Preferred Stock, at no charge, non-transferable subscription rights to purchase up to an aggregate of 20,000 units each consisting of one share of Series C Preferred Stock and 1,050 warrants for $1,000 per unit. Each warrant is exercisable for one share of the Company’s common stock at an exercise price of $0.7986 per share for 30 months from the date of issuance and each share of Series C Preferred Stock is convertible into 1,253 shares of the Company's common stock. Pursuant to the 2018 Rights Offering, which closed on July 25, 2018, the Company sold an aggregate of 6,723 units, resulting in total net proceeds to the Company of approximately $5.7 million.

Based on the relevant authoritative accounting guidance, the warrants were liability classified at the issuance date. The warrants may be redeemed by the Company at $0.01 per warrant prior to their expiration if the Company’s common stock closes above $3.63 per share, subject to adjustment, for 20 consecutive trading days. The initial fair value of the liability associated with these warrants was $3.1 million, and the fair value decreased to $1.5 million as of September 30, 2018. The main driver for the change in the fair value of warrants at September 30, 2018, was related to the change in our stock price. All future changes in the fair value of the warrants will be recognized in our consolidated statements of operations until they are either exercised or expire. The warrants are not traded in an active securities market, and as such the estimated the fair value as of September 30, 2018 was determined by using an option pricing model with the following assumptions:


	As of September 30, 2018			As of July 25, 2018 (inception date)
Expected term	2.3 years			2.5 years
Common stock market price	$	0.41	$	0.72
Risk-free interest rate		2.83%		2.70%
Expected volatility		120%		112%
Resulting fair value (per warrant)	$	0.21	$	0.45

Expected volatility was computed using daily pricing observations of traded shares of Cytori for recent periods that correspond to the expected term of the warrants. We believe this method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants. We currently have no reason to believe future volatility over the expected remaining life of these warrants is likely to differ materially from historical volatility. The expected life is based on the remaining contractual term of the warrants. The risk-free interest rate is the U.S. Treasury bond rate as of the valuation date.

Fluctuations in the fair value of the warrants are impacted by unobservable inputs, most significantly the assumption with regards to future equity issuances and its impact to the down-round protection feature. Significant increases (decreases) in this input in isolation would result in a significantly higher (lower) fair value measurement. The following table summarizes the change in our Level 3 warrant liability value (in thousands):

		Nine months ended
Warrant liability		September 30, 2018
Beginning balance	$	3,148
Change in fair value		(1,676	)
Ending balance	$	1,472

The fair value of the common stock into which the Series C Preferred Stock was convertible on the date of issuance exceeded the proceeds allocated to the preferred stock, resulting in the beneficial conversion feature that we recognized as a deemed dividend to the preferred stockholders and, accordingly, an adjustment to net loss to arrive at net loss allocable to common stockholders. We recorded a deemed dividend within additional paid-in capital of $2.5 million for the quarter ended September 30, 2018, related to a beneficial conversion feature included in the issuance of our Series C Convertible Preferred Stock. There were 3,510 shares of Series C Preferred Stock outstanding as of September 30, 2018.

Common Stock

On April 11, 2017, we entered into the Underwriting Agreement with Maxim relating to the issuance and sale of 0.9 million shares of our common stock. The price to the public in the offering was $11.00 per share. Maxim purchased the shares from us pursuant to the Underwriting Agreement at a price of $10.40 per share. The net proceeds to us from the offering were approximately $8.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed on April 17, 2017. In addition, under the terms of the Underwriting Agreement, we granted Maxim a 45-day overallotment option to purchase up to 94,400 additional shares of common stock. On May 31, 2017, Maxim exercised their overallotment option and purchased 84,900 shares at $11.00 per share. The net proceeds to us were $0.8 million, after deducting underwriting costs and offering expenses payable by us.

On June 1, 2018, the Company entered into a Sales Agreement with B. Riley FBR to sell shares of its common stock having an aggregate offering price of up to $6.5 million through its ATM program. Through September 30, 2018, the Company sold a total of 1.5 million shares for proceeds of approximately $0.8 million through the ATM program.

On September 21, 2018, the Company entered into a Purchase Agreement (the “Lincoln Park Purchase Agreement”) with Lincoln Park pursuant to which the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $5.0 million of shares, of the Company’s common stock, over the 24-month period following October 15, 2018. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 250,000 shares of common stock on any business day but in no event will the amount of a single Regular Purchase (as defined in the Lincoln Park Purchase Agreement) exceed $1.0 million. The purchase price of shares of common stock related to the Regular Purchases will be based on the prevailing market prices of such shares at the time of sales. The Company’s sales of shares of common stock to Lincoln Park under the Lincoln Park Purchase Agreement are limited to the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of no more than 4.99% of the then outstanding shares of the common stock. There are no trading volume requirements or restrictions under the Lincoln Park Purchase Agreement. There is no upper limit on the price per share that Lincoln Park must pay for common stock under a Regular Purchase or an accelerated purchase and in no event under an accelerated purchase will shares be sold to Lincoln Park on a day the closing price of the Company’s common stock is less than the floor price of $0.25 per share as set forth in the Lincoln Park Purchase Agreement.

Basis of Presentation and New Accounting Standards (Policies)	9 Months Ended
	Sep. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and New Accounting Standards	Our accompanying unaudited consolidated condensed financial statements as of September 30, 2018 and for the three and nine months ended September 30, 2018 and 2017 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at December 31, 2017 has been derived from the audited financial statements at December 31, 2017, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (collectively, the “Company”) have been included. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 9, 2018.
Recently Issued and Recently Adopted Accounting Pronouncements	Recently Issued and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases. Under this new guidance, at the commencement date, lessees will be required to recognize (i) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and (ii) a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. This guidance is not applicable for leases with a term of 12 months or less. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted. Although ASU 2016-02 is required to be adopted at the earliest period presented using a modified retrospective approach, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which allows for an alternative transition method of adoption by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company plans to adopt ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11. Although the Company is in the process of evaluating the impact the adoption of ASU 2016-02 will have on its financial statements, the Company expects the most significant changes will be the recognition of right-of-use assets and lease liabilities on the Company’s balance sheet for its real estate operating lease commitments. In February 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, to simplify how all entities assess goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As amended, the goodwill impairment test will consist of one step comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact that this standard will have on our consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 31, 2018, with early adoption permitted. We are currently evaluating the impact that this standard will have on our consolidated financial statements. Recently Adopted Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services. ASU 2014-09 and all subsequent amendments (collectively, the “new standards”) may be applied using either the full retrospective method, in which case the standard would be applied to each prior reporting period presented, or the modified retrospective method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application. We have adopted the standards beginning this first quarter of 2018 using the modified retrospective method. Overall, the timing or amounts related to the revenue recognition under the new standards did not differ from our previously applied revenue recognition policy. Our product revenues are recognized at a point in time, which is when control transfers to the customer. We have made an accounting policy election to treat shipping and handling activities that occur after the customer obtains control of the goods as fulfillment costs. There was no cumulative effect of applying the new standards as of the adoption date on January 1, 2018. In November 2016, the FASB issued ASU 2016-18, Restricted Cash, which requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The adoption of this standard, in the first quarter of 2018, changed the presentation of our statement of cash flows to include our restricted cash balance with the non-restricted cash balances. The new guidance did not have a material impact on the Company's consolidated financial statements. Cash, cash equivalents, and restricted cash reported on the consolidated condensed statements of cash flows includes restricted cash of $0.4 million, $0.4 million, $0.7 million, and $40,000 as of December 31, 2016, September 30, 2017, December 31, 2017 and September 30, 2018, respectively.
Use of Estimates	The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, valuing warrants, measuring expense related to our in-process research and development acquisition, and valuing allowances for doubtful accounts and inventory reserves. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.
Revenue Recognition	The Company’s contracts with customers only include one performance obligation (i.e., sale of the Company’s products). Typically, if there are multiple items included on a single order, they are delivered at the same time. Revenue is recognized at a point in time when delivery is completed and control of the promised goods is transferred to the customers. Revenue is measured as the amount of consideration the Company expects to be entitled to in exchange for those goods. The Company’s contracts do not involve financing elements as payment terms with customers are less than one year. The sale arrangements do not include any variable consideration. Advance payments from customers are recorded as deferred revenue. Shipping and handling activities that occur after the customer obtains control of the goods are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred.

Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2018

Revenue Recognition [Abstract]

Revenue by Product

The following table represents revenue by product (in thousands):

	Three months ended				Nine months ended
	September 30, 2018		September 30, 2017		September 30, 2018		September 30, 2017
Consumable	$	692	$	389	$	1,845	$	1,338
Device		101		25		194		551
Other products		65		53		210		138
	$	858	$	467	$	2,249	$	2,027

Product Revenues, Classified by Geographic Location

Product revenues, classified by geographic location, are as follows (in thousands):

	Three months ended										Nine months ended
	September 30, 2018					September 30, 2017					September 30, 2018					September 30, 2017
	Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total
Americas	$	199		23	%	$	112		24	%	$	249		11	%	$	315		15	%
Japan		535		62	%		279		60	%		1,693		75	%		1,434		71	%
EMEA		114		14	%		18		4	%		262		12	%		204		10	%
Asia Pacific		10		1	%		58		12	%		45		2	%		74		4	%
Total product revenues	$	858		100	%	$	467		100	%	$	2,249		100	%	$	2,027		100	%

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

Stockholders Equity Note [Abstract]

Schedule of Estimated Fair Value Determined Using Option Pricing Model Assumptions

The warrants are not traded in an active securities market, and as such the estimated the fair value as of September 30, 2018 was determined by using an option pricing model with the following assumptions:


	As of September 30, 2018			As of July 25, 2018 (inception date)
Expected term	2.3 years			2.5 years
Common stock market price	$	0.41	$	0.72
Risk-free interest rate		2.83%		2.70%
Expected volatility		120%		112%
Resulting fair value (per warrant)	$	0.21	$	0.45

Summary of Change in Level 3 Warrant Liability Value

The following table summarizes the change in our Level 3 warrant liability value (in thousands):

		Nine months ended
Warrant liability		September 30, 2018
Beginning balance	$	3,148
Change in fair value		(1,676	)
Ending balance	$	1,472

Basis of Presentation and New Accounting Standards (Details)	May 23, 2018 $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	May 24, 2018 shares	Dec. 31, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	Dec. 31, 2016 USD ($)
Basis Of Presentation And New Accounting Standards [Line Items]
Reverse stock split of common stock	0.1
Common stock, par value (in dollars per share) \| $ / shares	$ 0.001	$ 0.001		$ 0.001
Common stock, shares authorized (in shares)	75,000,000	100,000,000	100,000,000	100,000,000
Common stock, shares issued (in shares)	61,600,000	11,691,293	6,200,000	5,782,573
Common stock, shares outstanding (in shares)	61,600,000	11,691,293	6,200,000	5,782,573
Number of shares callable by warrants (in shares)	23,400,000		2,300,000
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000	5,000,000	5,000,000
Common stock, reverse stock split, fractional shares issued	0
Accounting Standards Update No. 2016-18 [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Restricted cash \| $		$ 40,000		$ 700,000	$ 400,000	$ 400,000
2014 Equity Incentive Plan [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of shares callable by warrants (in shares)	9,100,000		900,000

Liquidity (Details) - USD ($)										3 Months Ended		4 Months Ended	9 Months Ended
Liquidity (Details) - USD ($)	Sep. 21, 2018	Aug. 31, 2018	Aug. 28, 2018	Jul. 25, 2018	Jun. 01, 2018	Nov. 28, 2017	Sep. 05, 2017	May 31, 2017	Apr. 11, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	May 24, 2018	May 23, 2018	Dec. 31, 2017
Liquidity [Line Items]
Net loss										$ 2,330,000	$ 4,807,000		$ 10,398,000	$ 18,399,000
Accumulated deficit										412,147,000		$ 412,147,000	412,147,000				$ 401,749,000
Net cash used in operating activities													9,487,000	$ 13,904,000
Aggregate pincipal payments		$ 7,000,000
Cash and cash equivalents										6,806,000		6,806,000	6,806,000				$ 9,550,000
Minimum cash/cash equivalents covenant										1,500,000		$ 1,500,000	$ 1,500,000
Common stock issued (in shares)				6,723		10,000
Number of shares callable by warrants (in shares)															2,300,000	23,400,000
Proceeds from issuance warrants				$ 5,700,000		$ 8,800,000
Series B Convertible Preferred Stock [Member]
Liquidity [Line Items]
Common stock issued (in shares)						3,000,000
Number of shares callable by warrants (in shares)						18,000,000
Series C Convertible Preferred Stock [Member]
Liquidity [Line Items]
Number of shares callable by warrants (in shares)				7,059,150
Number of convertible shares converted into common stock (in shares)				8,400,000
Nasdaq Stock Market LLC [Member]
Liquidity [Line Items]
Number of consecutive business days no longer able to meet the required closing bid price of common stock			30 days				30 days
Minimum bid price of common stock required for Nasdaq listing rule			$ 1				$ 1
Grace period provided with minimum bid price for Nasdaq listing rule			180 days				180 days
Grace date for minimum bid price requirement for Nasdaq listing			Feb. 25, 2019				Mar. 05, 2018
Common stock minimum bid price required to regain compliance			$ 1				$ 1
Number of consecutive business days required to regain compliance			10 days				10 days
Additional grace period provided with minimum bid price to regain compliance			180 days				180 days
Description of compliance with minimum bid price requirement													In the event we do not regain compliance within this 180-day period, we may be eligible to seek an additional compliance period of 180 calendar days if we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, if we provide written notice to Nasdaq of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary
Common Stock [Member]
Liquidity [Line Items]
Common stock issued (in shares)				6,723		10,000
Share issued, price per share									$ 11.00
Number of shares callable by warrants (in shares)				1		1,800,000
Warrant exercise price (in dollars per share)				$ 0.7986		$ 3.333
Common Stock [Member] \| Lincoln Park [Member]
Liquidity [Line Items]
Common stock issued, value	$ 5,000,000
Period exercisable from the date of issuance	24 months
Common Stock [Member] \| Maxim Group LLC [Member]
Liquidity [Line Items]
Common stock issued (in shares)								84,900	900,000
Share issued, price per share								$ 11.00	$ 10.40
Proceeds from sale of common stock, net								$ 800,000	$ 8,700,000
Closing of offering date									Apr. 17, 2017
Number of days granted as option to purchase additional shares of common stock to underwriter									45 days
Additional shares of common stock									94,400
Common Stock [Member] \| ATM Program [Member] \| B. Riley FBR [Member] \| Sales Agreement [Member]
Liquidity [Line Items]
Common stock issued (in shares)												1,500,000
Proceeds from sale of common stock, net												$ 800,000
Minimum [Member]
Liquidity [Line Items]
Unrestricted cash and cash equivalents										$ 1,500,000		$ 1,500,000	$ 1,500,000
Maximum [Member] \| Common Stock [Member] \| ATM Program [Member] \| B. Riley FBR [Member] \| Sales Agreement [Member]
Liquidity [Line Items]
Proceeds from sale of common stock, net					$ 6,500,000

Term Loan Obligations (Details) - USD ($)					3 Months Ended		9 Months Ended
Term Loan Obligations (Details) - USD ($)	Aug. 31, 2018	Jun. 19, 2018	Dec. 29, 2017	May 29, 2015	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	May 24, 2018	May 23, 2018	Sep. 20, 2017
Debt Instrument [Line Items]
Number of shares callable by warrants (in shares)									2,300,000	23,400,000
Minimum liquidity covenant					$ 1,500,000		$ 1,500,000
Minimum amount to be paid pursuant prepayment requirement	$ 7,000,000
Interest expense					512,000	$ 474,000	1,379,000	$ 1,603,000
Non-cash amortization					200,000	$ 200,000	$ 400,000	$ 600,000
LIBOR [Member] \| Interest Rate Floor [Member]
Debt Instrument [Line Items]
Basis variable rate				1.00%
Term Loan [Member]
Debt Instrument [Line Items]
Origination Date							May 29, 2015
Original Loan Amount				$ 17,700,000
Basis variable rate				7.95%
Maturity date							Jun. 01, 2019
Fees amount associated with loan				$ 1,100,000
Number of shares callable by warrants (in shares)				9,444
Warrant exercise price (in dollars per share)				$ 103.50
Date from which warrants are exercisable							Nov. 30, 2015
Warrant expiration date							May 29, 2025
Minimum liquidity covenant				$ 5,000,000							$ 1,500,000
Extended interest-only period	Dec. 31, 2018	Dec. 01, 2018					Aug. 01, 2018
Debt instrument, interest-only period	The Third Amendment extends the interest-only period under the Term Loan to December 31, 2018 and also requires that the Company pay to Oxford, in accordance with its pro rata share of the loans, 75% of all proceeds received (i) from the issuance and sale of unsecured subordinated convertible debt, (ii) in connection with a joint venture, collaboration or other partnering transaction, (iii) in connection with any licenses, (iv) from dividends (other than non-cash dividends from wholly owned subsidiaries) and (v) from the sale of any assets (such requirement, the “Prepayment Requirement”).	The Second Amendment extends the interest-only period under the Term Loan to December 1, 2018 if the Company receives unrestricted gross cash proceeds of at least $15 million from the sale and issuance of the Company’s equity securities on or before August 31, 2018.					The amendment also extended the interest-only period under the Loan Agreement through August 1, 2018, as the Company successfully closed on a financing and received unrestricted net cash proceeds in excess of $5 million on or before December 29, 2017.
Net proceeds excess receives from unrestricted cash			$ 5,000,000
Amendment fee	$ 50,000	$ 250,000
Percentage of proceeds received	75.00%
Minimum amount to be paid pursuant prepayment requirement	$ 7,000,000
Debt instrument prepayment, description	The Prepayment Requirement does not apply to proceeds from the sale and issuance of the Company’s equity securities, other than convertible debt. The Prepayment Requirement shall apply until an aggregate principle amount of $7.0 million has been paid pursuant to the Prepayment Requirement. However, if less than $7.0 million has been paid pursuant to the Prepayment Requirement on December 31, 2018 then the Company is required to promptly make additional payments until an aggregate principal amount of $7.0 million has been paid.
Debt instrument, covenant compliance							we were in compliance with all of the debt covenants under the Loan and Security Agreement.
Minimum [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Interest rate				8.95%
Unrestricted gross cash proceeds required to extend interest-only period		$ 15,000,000
Maximum [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Original Loan Amount					$ 3,000,000		$ 3,000,000

Commitments and Contingencies (Details) - USD ($) $ in Thousands				3 Months Ended		9 Months Ended
	Oct. 29, 2018	Aug. 31, 2018	Feb. 27, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Apr. 27, 2018	Dec. 31, 2017	Jan. 27, 2017
Recorded Unconditional Purchase Obligation [Line Items]
Initial term of lease			63 months
Lease commencement date			Jan. 01, 2018
Buy-out of obligations lease			$ 600
Common stock, aggregate amount				$ 67		$ 67			$ 58
Gross profit from sale of company’s puregraft product line				230	$ (20)	$ 412	$ 116
Lorem Vascular [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Percentage of common stock to be purchased								5.00%
Common stock, aggregate amount								$ 5,000
Amended complaint dismissal date						Oct. 01, 2018
Bimini Technologies LLC \| Demand for Arbitration [Member] \| Sale and Exclusive License/Supply Agreement [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Potential milestone payment due upon acheivement of gross profit		$ 1,000
Gross profit from sale of company’s puregraft product line		10,000
Potential milestone payment claimed		$ 1,000
Bimini Technologies LLC \| Demand for Arbitration [Member] \| Sale and Exclusive License/Supply Agreement [Member] \| Subsequent Event [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Proceeds from milestone payment	$ 1,000
Japan Lease [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Initial term of lease										61 months
Lease commencement date						Apr. 15, 2017
Pre-clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation, due in next twelve months				1,700		$ 1,700
Contractual obligation				$ 3,200		$ 3,200

Asset Purchase Agreement with Azaya Therapeutics - Additional Information (Details) - Assets Purchased from Azaya Therapeutics, Inc. [Member] $ in Thousands		9 Months Ended
	Feb. 15, 2017 USD ($) Candidate shares	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Business Acquisition [Line Items]
Total consideration	$ 4,300
Fair value of the common stock issued	2,300
Assumed liabilities	1,800
Acquisition costs	200
In process research and development expense	1,700	$ 0	$ 1,686
Asset Purchase Agreement
Business Acquisition [Line Items]
Book value of tangible assets acquired	$ 3,000
Common stock, shares issued \| shares	117,325
Common stock, shares issued after closing date \| shares	87,994
Common stock deposited in escrow \| shares	29,331
Obligation to pay on existing payables assumed	$ 1,800
Existing payables, paid during the period				$ 1,800
Asset Purchase Agreement \| IPR&D [Member]
Business Acquisition [Line Items]
Number of drug candidates acquired \| Candidate	2

Stockholders' Equity - Preferred Stock (Details) - USD ($)				9 Months Ended	12 Months Ended
	Jul. 25, 2018	Jul. 17, 2018	Nov. 28, 2017	Sep. 30, 2018	Dec. 31, 2017	May 24, 2018	May 23, 2018
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)				5,000,000	5,000,000	5,000,000	5,000,000
Preferred stock, par value (in dollars per share)				$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)				23,500	23,500
Preferred stock, shares outstanding (in shares)				4,624	2,431
Number of shares callable by warrants (in shares)						2,300,000	23,400,000
Common stock issued (in shares)	6,723		10,000
Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)	1		1,800,000
Warrant exercise price (in dollars per share)	$ 0.7986		$ 3.333
Common stock issued (in shares)	6,723		10,000
2018 Rights Offering [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1
Warrant exercise price (in dollars per share)		$ 0.7986
Period exercisable from the date of issuance				30 months
Common stock issued (in shares)	6,723
Gross proceeds from private placement of stock	$ 5,700,000
Redemption price of warrant prior to expiration				$ 0.01
Common stock price per share for warrant redemption				$ 3.63
Number of consecutive trading days for warrant redemption				20 days
Warrants liability fair value				$ 1,500,000	$ 3,100,000
2018 Rights Offering [Member] \| Warrant [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1,050
Warrant exercise price (in dollars per share)		$ 1,000
2018 Rights Offering [Member] \| Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1
Series A Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares issued (in shares)				13,500	13,500
Convertible preferred stock				3.60%	3.60%
Preferred stock, shares outstanding (in shares)				0	0
Series B Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares issued (in shares)				10,000	10,000
Preferred stock, shares outstanding (in shares)				1,114	2,431
Number of shares callable by warrants (in shares)			18,000,000
Common stock issued (in shares)			3,000,000
Series C Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)	7,000
Preferred stock, par value (in dollars per share)	$ 0.001
Preferred stock, shares outstanding (in shares)				3,510
Number of shares callable by warrants (in shares)	7,059,150
Number of share converted into common stock for each share (in shares)	1,253
Series C Convertible Preferred Stock [Member] \| Dividend Paid [Member]
Preferred Stock [Abstract]
Dividends payable				$ 2,500,000
Series C Convertible Preferred Stock [Member] \| 2018 Rights Offering [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		20,000
Common Stock and Series B Convertible Preferred Stock [Member] \| 2018 Rights Offering [Member]
Preferred Stock [Abstract]
Charge on Non Transferable Subscription Rights		$ 0

Stockholders' Equity - Common Stock (Details) - USD ($)							4 Months Ended
Stockholders' Equity - Common Stock (Details) - USD ($)	Sep. 21, 2018	Jul. 25, 2018	Jun. 01, 2018	Nov. 28, 2017	May 31, 2017	Apr. 11, 2017	Sep. 30, 2018
Common Stock [Abstract]
Common stock issued (in shares)		6,723		10,000
Common Stock [Member]
Common Stock [Abstract]
Common stock issued (in shares)		6,723		10,000
Share issued, price per share						$ 11.00
Common Stock [Member] \| Maxim Group LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)					84,900	900,000
Share issued, price per share					$ 11.00	$ 10.40
Proceeds from sale of common stock, net					$ 800,000	$ 8,700,000
Closing of offering date						Apr. 17, 2017
Number of days granted as option to purchase additional shares of common stock to underwriter						45 days
Additional shares of common stock						94,400
Common Stock [Member] \| B. Riley FBR [Member] \| ATM Program [Member] \| Sales Agreement [Member]
Common Stock [Abstract]
Common stock issued (in shares)							1,500,000
Proceeds from sale of common stock, net							$ 800,000
Common Stock [Member] \| B. Riley FBR [Member] \| ATM Program [Member] \| Sales Agreement [Member] \| Maximum [Member]
Common Stock [Abstract]
Proceeds from sale of common stock, net			$ 6,500,000
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued, value	$ 5,000,000
Period exercisable from the date of issuance	24 months
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member] \| Securities Purchase Agreement [Member]
Common Stock [Abstract]
Trading Volume of Common Shares	0
Upper Limit on the Price Per Share	$ 0
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member] \| Maximum [Member]
Common Stock [Abstract]
Beneficial ownership percentage of common stock outstanding	4.99%
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member] \| Maximum [Member] \| Single Regular Purchase [Member]
Common Stock [Abstract]
Common stock issued (in shares)	250,000
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member] \| Minimum [Member] \| Single Regular Purchase [Member]
Common Stock [Abstract]
Common stock issued, value	$ 1,000,000
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member] \| Purchase Agreement [Member] \| Maximum [Member]
Common Stock [Abstract]
Floor price of per share	$ 0.25

Revenue Recognition (Details) $ in Thousands	3 Months Ended		9 Months Ended
Revenue Recognition (Details) $ in Thousands	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) Obligation Customer	Sep. 30, 2017 USD ($) Customer
Concentration Risk [Line Items]
Number of performance obligation \| Obligation			1
Payment terms with customers			The Company’s contracts do not involve financing elements as payment terms with customers are less than one year.
Concentration risk percentage	100.00%	100.00%	100.00%	100.00%
Development revenue recognized \| $	$ 454	$ 1,306	$ 2,270	$ 2,856
Customer Concentration Risk [Member] \| Revenue Recognized [Member]
Concentration Risk [Line Items]
Number of customers			2	6
Concentration risk percentage			58.00%	61.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers			3	4
Concentration risk percentage			72.00%	78.00%

Revenue Recognition - Product Revenues, Classified by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Concentration Risk [Line Items]
Revenues	$ 858	$ 467	$ 2,249	$ 2,027
Concentration risk percentage	100.00%	100.00%	100.00%	100.00%
Americas [Member]
Concentration Risk [Line Items]
Revenues	$ 199	$ 112	$ 249	$ 315
Concentration risk percentage	23.00%	24.00%	11.00%	15.00%
Japan [Member]
Concentration Risk [Line Items]
Revenues	$ 535	$ 279	$ 1,693	$ 1,434
Concentration risk percentage	62.00%	60.00%	75.00%	71.00%
EMEA [Member]
Concentration Risk [Line Items]
Revenues	$ 114	$ 18	$ 262	$ 204
Concentration risk percentage	14.00%	4.00%	12.00%	10.00%
Asia Pacific [Member]
Concentration Risk [Line Items]
Revenues	$ 10	$ 58	$ 45	$ 74
Concentration risk percentage	1.00%	12.00%	2.00%	4.00%

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 698	$ 681
Work in process	418	722
Finished goods	1,698	1,780
Inventory, net	$ 2,814	$ 3,183

Loss per Share (Details) - shares shares in Millions	9 Months Ended
Loss per Share (Details) - shares shares in Millions	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	14.1	0.5
Outstanding Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	9.2
Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	0.2
Preferred Stock and Restricted Stock Awards [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	4.7

Stockholders' Equity - Schedule of Estimated Fair Value Determined Using Option Pricing Model Assumptions (Details)	Sep. 30, 2018 $ / shares	Jul. 25, 2018 $ / shares
Expected Term [Member]
Class Of Stock [Line Items]
Warrants expected term	2 years 3 months 18 days	2 years 6 months
Common Stock Market Price [Member]
Class Of Stock [Line Items]
Warrants measurement input	0.41	0.72
Risk-free Interest Rate [Member]
Class Of Stock [Line Items]
Warrants measurement input	0.0283	0.0270
Expected Volatility [Member]
Class Of Stock [Line Items]
Warrants measurement input	1.20	1.12
Resulting Fair Value (Per Warrant) [Member]
Class Of Stock [Line Items]
Warrants measurement input	0.21	0.45

Stockholders' Equity - Summary of Change in Level 3 Warrant Liability Value (Details) - Warrant Liability [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2018 USD ($)
Warrant liability
Beginning balance	$ 3,148
Change in fair value	(1,676)
Ending balance	$ 1,472